Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas 77030, USA.
Adham S
AS
Bear
Richard A
RA
Morgan
Kenneth
K
Cornetta
Carl H
CH
June
Gwendolyn
G
Binder-Scholl
Mark E
ME
Dudley
Steven A
SA
Feldman
Steven A
SA
Rosenberg
Sheila A
SA
Shurtleff
Cliona M
CM
Rooney
Helen E
HE
Heslop
Gianpietro
G
Dotti
D000818:Animals; D002460:Cell Line; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D012190:Retroviridae / Q000235:genetics* / Q000502:physiology; D013601:T-Lymphocytes / Q000378:metabolism*; D018675:Toxicity Tests / Q000191:economics / Q000592:standards; D014161:Transduction, Genetic; D014779:Virus Replication / Q000235:genetics*